systematic identification genomic markers drug sensitivity cancer cells 
clinical responses anticancer therapies often restricted subset patients cases mutated cancer genes potent biomarkers responses targeted agents uncover new biomarkers sensitivity resistance cancer therapeutics screened panel several hundred cancer cell lines-which represent much tissue-type genetic diversity human cancers-with drugs clinical preclinical investigation aggregate found mutated cancer genes associated cellular response currently available cancer drugs classic oncogene addiction paradigms modified additional tissue-specific expression biomarkers frequently mutated genes associated sensitivity broad range therapeutic agents unexpected relationships revealed including marked sensitivity ewings sarcoma cells harbouring ews also known ewsr1-fli1 gene translocation polyadp-ribose polymerase parp inhibitors linking drug activity functional complexity cancer genomes systematic pharmacogenomic profiling cancer cell lines provides powerful biomarker discovery platform guide rational cancer therapeutic strategies 
